IRVINE, Calif., Nov. 07, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at four investor conferences in November 2016. The first conference is the Stephens 2016 Fall Investment Conference in New York, NY.
| Event: | Stephens 2016 Fall Investment Conference | ||
| Date: | Wednesday, November 9, 2016 | ||
| Time: | 11:00 am ET / 8:00 am PT | ||
| Participant: | Vaseem Mahboob, Chief Financial Officer | ||
The second conference is the Stifel 2016 Healthcare Conference in New York, NY.
| Event: | Stifel 2016 Healthcare Conference | ||
| Date: | Tuesday, November 15, 2016 | ||
| Time: | 11:00 am ET / 8:00 am PT | ||
| Participant: | John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer | ||
The third conference is the Canaccord Genuity Medical Technologies and Diagnostics Forum in New York, NY.
| Event: | Canaccord Genuity Medical Technologies and Diagnostics Forum | ||
| Date: | Thursday, November 17, 2016 | ||
| Time: | 8:30 am ET / 5:30 am PT | ||
| Participant: | John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer | ||
The fourth conference is the 28th Annual Piper Jaffray Healthcare Conference in New York, NY.
| Event: | 28th Annual Piper Jaffray Healthcare Conference | ||
| Date: | Wednesday, November 30, 2016 | ||
| Time: | 9:30 am ET / 6:30 am PT | ||
| Participant: | Vaseem Mahboob, Chief Financial Officer | ||
An audio webcast of the Company’s presentations will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentations will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020


Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 



